NuVasive's Pulse spine platform surpassed 2,000 commercial cases since it was released in 2021, CEO Chris Barry said in a fourth-quarter earnings call.
Pulse can be used in 100 percent of spine procedures, and NuVasive has new software expected to launch for the platform later in 2023. Mr. Barry said in the Feb. 22 earnings call, according to Seeking Alpha. Mr. Barry said there's a "broad pipeline of technlogy" ahead for Pulse, and the company plans to leverage its upcoming merger with Globus Medical.
"We've always talked about pursuing robotics in the future for Pulse," Mr. Barry said. "It's always been a part of the road map, and it still is. So the opportunity we see ahead with Globus [Medical] accelerates our opportunity with robotics, enabling tech in general."